Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer.
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Turaka A, et al. Among authors: burtness b. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):65-70. doi: 10.1016/j.ijrobp.2009.10.034. Epub 2010 Apr 10. Int J Radiat Oncol Biol Phys. 2011. PMID: 20385457 Free PMC article.
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA; Eastern Cooperative Oncology Group. Burtness BA, et al. Ann Oncol. 2008 May;19(5):977-83. doi: 10.1093/annonc/mdm591. Epub 2008 Feb 21. Ann Oncol. 2008. PMID: 18296423 Free article. Clinical Trial.
Head and neck cancers.
National Comprehensive Cancer Network; Forastiere AA, Ang KK, Brizel D, Brockstein BE, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Goepfert H, Hicks WL Jr, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pfister DG, Pinto HA, Posner MR, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf GT, Worden F. National Comprehensive Cancer Network, et al. Among authors: burtness ba. J Natl Compr Canc Netw. 2008 Aug;6(7):646-95. doi: 10.6004/jnccn.2008.0051. J Natl Compr Canc Netw. 2008. PMID: 18691457 No abstract available.
Targeting EGFR resistance networks in head and neck cancer.
Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Ratushny V, et al. Cell Signal. 2009 Aug;21(8):1255-68. doi: 10.1016/j.cellsig.2009.02.021. Epub 2009 Mar 1. Cell Signal. 2009. PMID: 19258037 Free PMC article. Review.
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Rusthoven KE, et al. Among authors: burtness b. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1020-5. doi: 10.1016/j.ijrobp.2009.09.003. Epub 2010 Mar 16. Int J Radiat Oncol Biol Phys. 2010. PMID: 20231078 Clinical Trial.
273 results